Entrar Registro gratuito

Last updated: 21 June 2024 at 6:45pm EST

Tanisha Carino Net Worth




The estimated Net Worth of Tanisha Carino is at least $3.14 Milhão dollars as of 2 December 2020. Ms. Carino owns over 1,530 units of Alexion Pharmaceuticals stock worth over $2,947,954 and over the last 5 years she sold ALXN stock worth over $187,058. In addition, she makes $0 as Executive Vice President e Chief Corporate Affairs Officer at Alexion Pharmaceuticals.

Ms. Carino ALXN stock SEC Form 4 insiders trading

Tanisha has made over 1 trades of the Alexion Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 1,530 units of ALXN stock worth $187,058 on 2 December 2020.

The largest trade she's ever made was selling 1,530 units of Alexion Pharmaceuticals stock on 2 December 2020 worth over $187,058. On average, Tanisha trades about 153 units every 0 days since 2019. As of 2 December 2020 she still owns at least 16,102 units of Alexion Pharmaceuticals stock.

You can see the complete history of Ms. Carino stock trades at the bottom of the page.





Tanisha Carino biography

Tanisha Carino Ph.D. serves as Executive Vice President, Chief Corporate Affairs Officer of the Company. She is Executive Vice President, Chief Corporate Affairs Officer of Alexion. In this role, Dr. Carino is responsible for global government relations, policy and communications. Prior to joining Alexion in November 2019, Dr. Carino served as Executive Director of FasterCures, a Center of the Milken Institute, a nonpartisan think tank whose mission is working with global government, philanthropic, and business leaders to accelerate treatments to patients from January 2018 to November 2019. Prior to leading FasterCures, from May 2015 to January 2018, Dr. Carino was an executive at GlaxoSmithKline where she led the United States policy function, and spent over a decade with Avalere Health, a strategic advisory services organization, where she worked with senior leaders of life sciences companies to maximize opportunities and mitigate challenges related to biomedical research and patient access. She also worked in the U.S. Medicare program to improve access for its beneficiaries and support the development of real-world evidence. Dr. Carino is a Fulbright Fellow, earned her Ph.D. in health policy from Johns Hopkins University, and is associate faculty at the Johns Hopkins Bloomberg School of Public Health.



How old is Tanisha Carino?

Tanisha Carino is 45, she's been the Executive Vice President e Chief Corporate Affairs Officer of Alexion Pharmaceuticals since 2019. There are 16 older and no younger executives at Alexion Pharmaceuticals. The oldest executive at Alexion Pharmaceuticals Inc. is John Mollen, 69, who is the Independent Director.

What's Tanisha Carino's mailing address?

Tanisha's mailing address filed with the SEC is 1213 INNSBRUCK DRIVE, , SUNNYVALE, CA, 94089.

Insiders trading at Alexion Pharmaceuticals

Over the last 21 years, insiders at Alexion Pharmaceuticals have traded over $451,742,532 worth of Alexion Pharmaceuticals stock and bought 2,576,434 units worth $277,855,180 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Leonard Bell, ePaul A Friedman. On average, Alexion Pharmaceuticals executives and independent directors trade stock every 9 days with the average trade being worth of $3,460,578. The most recent stock trade was executed by Daniel Bazarko on 17 December 2020, trading 24,066 units of ALXN stock currently worth $2,816,685.



What does Alexion Pharmaceuticals do?

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.



What does Alexion Pharmaceuticals's logo look like?

Alexion Pharmaceuticals Inc. logo

Complete history of Ms. Carino stock trades at Alexion Pharmaceuticals e Silk Road Medical Inc

Data
#
Companhia
 Acionista maioritário
Trans.
Transação
 Ações Preço por ação Preço total Ações após Fonte
2 Dec 2020 ALXN Alexion Pharmaceuticals Inc. Tanisha Carino
EVP e CCAO
 Venda 1,530 $122.26 $187,058
2 Dec 2020
16,102 ↗


Alexion Pharmaceuticals executives and stock owners

Alexion Pharmaceuticals executives and other stock owners filed with the SEC include: